PRECIGEN, INC. Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest
PRECIGEN, INC. (PGEN) reported Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest of -$39.68 million for the 3-month period ending 2020-12-31, per its 10-K filed 2021-03-01.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest · last filed 2021-03-01
- PRECIGEN, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2020-12-31 was -$39.68M.
- PRECIGEN, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2020-09-30 was -$27.54M.
- PRECIGEN, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2020-06-30 was -$15.71M.
- PRECIGEN, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2020-03-31 was -$20.85M.
| Period end | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month as first filed | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|---|
| 2020-12-31 | -$39.68M 10-K · filed 2021-03-01 | -$67.22M derived: sum of 2 quarters · filed 2021-03-01 | -$82.93M derived: sum of 3 quarters · filed 2021-03-01 | -$103.77M derived: sum of 4 quarters · filed 2021-03-01 | |
| 2020-09-30 | -$27.54M 10-K · filed 2021-03-01 | -$43.24M derived: sum of 2 quarters · filed 2021-03-01 | -$64.09M derived: sum of 3 quarters · filed 2021-03-01 | -$128.33M derived: sum of 4 quarters · filed 2021-03-01 | |
| 2020-06-30 | -$15.71M 10-K · filed 2021-03-01 | -$36.55M derived: sum of 2 quarters · filed 2021-03-01 | -$100.79M derived: sum of 3 quarters · filed 2021-03-01 | -$139.91M derived: sum of 4 quarters · filed 2021-03-01 | |
| 2020-03-31 | -$20.85M 10-K · filed 2021-03-01 | -$85.08M derived: sum of 2 quarters · filed 2021-03-01 | -$124.20M derived: sum of 3 quarters · filed 2021-03-01 | -$146.64M derived: sum of 4 quarters · filed 2021-03-01 | |
| 2019-12-31 | -$64.24M 10-K · filed 2021-03-01 | -$73.50M 10-K · filed 2020-03-02 | -$103.36M derived: sum of 2 quarters · filed 2021-03-01 | -$125.80M derived: sum of 3 quarters · filed 2021-03-01 | -$170.33M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-09-30 | -$39.12M 10-K · filed 2021-03-01 | -$49.05M 10-K · filed 2020-03-02 | -$61.56M derived: sum of 2 quarters · filed 2021-03-01 | -$106.10M derived: sum of 3 quarters · filed 2021-03-01 | -$380.69M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | -$22.44M 10-K · filed 2021-03-01 | -$32.30M 10-K · filed 2020-03-02 | -$66.98M derived: sum of 2 quarters · filed 2021-03-01 | -$341.57M derived: sum of 3 quarters · filed 2021-03-01 | -$392.07M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | -$44.54M 10-K · filed 2021-03-01 | -$52.90M 10-K · filed 2020-03-02 | -$319.13M derived: sum of 2 quarters · filed 2021-03-01 | -$369.63M derived: sum of 3 quarters · filed 2021-03-01 | -$421.75M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | -$274.59M 10-K · filed 2020-03-02 | -$325.09M derived: sum of 2 quarters · filed 2020-03-02 | -$377.21M derived: sum of 3 quarters · filed 2020-03-02 | -$414.32M derived: sum of 4 quarters · filed 2020-03-02 | |
| 2018-09-30 | -$50.51M 10-K · filed 2020-03-02 | -$102.63M derived: sum of 2 quarters · filed 2020-03-02 | -$139.73M derived: sum of 3 quarters · filed 2020-03-02 | ||
| 2018-06-30 | -$52.12M 10-K · filed 2020-03-02 | -$89.22M derived: sum of 2 quarters · filed 2020-03-02 | |||
| 2018-03-31 | -$37.10M 10-K · filed 2020-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |